Hegt V N
Thromb Haemost. 1977 Aug 31;38(2):407-19.
From systematic studies of both the activation and the inhibition of fibrinolysis in human blood vessels, data which provided insight into the fibrinolysis antagonism along and across the human vessel wall were obtained. The capacity for fibrinolysis initiated by plasminogen activator in sections of human arteries and veins as demonstrated by the fibrin slide technique differed greatly along and across the vessel walls. Inhibition of plasmin fibrinolysis in these blood vessels as detected by the fibrin slide sandwich technique was present at sites of low fibrinolytic activity, while inhibition was absent in areas showing strong fibrinolysis. Fibrinolysis was related to endothelial cells, while inhibition of fibrinolysis was brought about by smooth muscle cells. The results indicate that differences in endothelial fibrinolysis may be the result of differences in inhibition of fibrinolysis caused by variations in the number of smooth muscle cells present locally. A systemic decrease in endothelial fibrinolysis observed in endotoxin shock, hyaline membrane disease and a Waterhouse-Friderichsen syndrome appeared to be associated with a systemic increase in inhibition of fibrinolysis not related to smooth muscle cells.
通过对人体血管中纤维蛋白溶解的激活和抑制进行系统研究,获得了有助于深入了解沿人体血管壁及跨血管壁纤维蛋白溶解拮抗作用的数据。用纤维蛋白玻片技术证实,人动脉和静脉切片中纤溶酶原激活物引发的纤维蛋白溶解能力在血管壁内外差异很大。用纤维蛋白玻片夹心技术检测发现,这些血管中纤维蛋白溶解活性低的部位存在纤溶酶纤维蛋白溶解抑制作用,而纤维蛋白溶解强烈的区域则不存在抑制作用。纤维蛋白溶解与内皮细胞有关,而纤维蛋白溶解的抑制是由平滑肌细胞引起的。结果表明,内皮纤维蛋白溶解的差异可能是局部平滑肌细胞数量变化导致纤维蛋白溶解抑制差异的结果。在内毒素休克、透明膜病和华-佛综合征中观察到的内皮纤维蛋白溶解的全身性降低,似乎与不涉及平滑肌细胞的纤维蛋白溶解抑制作用的全身性增加有关。